Ignite Creation Date:
2025-12-25 @ 3:53 AM
Ignite Modification Date:
2025-12-26 @ 2:43 AM
Study NCT ID:
NCT01190202
Status:
COMPLETED
Last Update Posted:
2020-08-18
First Post:
2010-08-26
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Epidemiology Study of Malaria Transmission Intensity in Africa
Sponsor:
GlaxoSmithKline
Organization:
Study Overview
Official Title:
Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
Status:
COMPLETED
Status Verified Date:
2020-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this epidemiology study is to characterize in a standardized way malaria transmission intensity at the clinical trial centers participating in study 110021 (NCT00866619).
Detailed Description:
This study is a multicenter epidemiology study at centers that are participating in GSK's pivotal Phase III candidate malaria vaccine 110021 ( NCT00866619) trial and will involve 4 annual cross sectional surveys performed preferably at peak transmission.
There will be no study vaccine administered in this epidemiology study.
There will be no study vaccine administered in this epidemiology study.
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: